Physician profile
Val D Warner
NPI 1366819575
$50,542.67
in general payments reported to CMS, 2019-2025
63 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $20K · 2023: $2,637 · 2024: $4,080 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,690 · Food and Beverage: $7,751 · Consulting Fee: $2,215 · Education: $32.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,690.00 |
| Food and Beverage | $7,750.79 |
| Consulting Fee | $2,215.00 |
| Education | $32.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $17,655.63 | 2021-2024 | Givlaari, Oxlumo |
| Pfizer INC. | $11,781.71 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $8,469.19 | 2021 | |
| Abbvie INC. | $4,114.21 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $1,093.93 | 2022 | |
| Novo Nordisk INC | $875.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $664.54 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $599.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $529.15 | 2021-2025 | |
| Axsome Therapeutics, INC. | $420.66 | 2022-2025 | Sunosi, Auvelity, Symbravo |
| Astellas Pharma US INC | $389.95 | 2021-2025 | Veozah, Myrbetriq |
| Nestle Healthcare Nutrition INC. | $255.31 | 2021-2023 | |
| Glaxosmithkline, LLC. | $243.87 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $241.04 | 2022-2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.32 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Val Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.